Setmelanotide Shows Promise in Hypothalamic Obesity

Source link :

TOPLINE: Setmelanotide treatment over a 16-week period leads to a consistent decrease in both bodyweight and hunger among patients with hypothalamic obesity, according to the results of the first known study investigating the use of this targeted treatment in this indication. METHODOLOGY: No approved treatments currently exist for hypothalamic obesity, a condition resulting from hypothalamic […]

Author : News Health

Publish date : 2024-05-15 09:14:52

Copyright for syndicated content belongs to the linked Source.